Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Intracellular retention of a functional vasopressin V2 receptor (V2R) is a major cause of congenital nephrogenic diabetes insipidus (NDI) and rescue of V2R mutants by nonpeptide antagonists may restore their basolateral membrane (BM) localization and function. However, the criteria for efficient functional rescue of G protein-coupled receptor (GPCR) mutants at clinically feasible antagonist concentrations are unknown. We found that the four nonpeptide antagonists SR49059, OPC31260, OPC41061, and SR121463B induced maturation and rescued the BM expression of eight of nine different V2R mutants, stably expressed in physiologically relevant polarized cells. The extent of maturation and rescued BM expression correlated with the antagonists' concentration and affinity for the V2R. Displacement of the antagonists by AVP and subsequent cAMP generation inversely correlated with the antagonists' affinities for the V2R but is partially influenced by antagonist-specific aspects. Despite limited increases in maturation and cell-surface expression of V2R mutants, the low-affinity SR49059 optimally induced functional rescue at high concentrations, due to its easy displacement by vasopressin. At clinically feasible antagonist concentrations, however, only the high-affinity antagonists OPC31260 and OPC41061 induced functional rescue, as at these concentrations the extent of BM expression became limited. In conclusion, functional rescue of mutant V2Rs at clinically feasible concentrations is most effective with high-affinity antagonists. As OPC31260 and OPC41061 are clinically safe, they are promising candidates to relieve NDI. Moreover, as numerous other diseases are caused by endoplasmic reticulum-retained GPCRs for which cell-permeable antagonists become available, our finding that high-affinity antagonists are superior is anticipated to be important for pharmacotherapy development of these diseases.
Robben
J H
JH
Department of Physiology, Nijmegen Centre for Molecular Life Sciences, The Netherlands.
Sze
M
M
Knoers
N V A M
NV
Deen
P M T
PM
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D000954:Antigens, Surface / Q000096:biosynthesis / Q000235:genetics; D001667:Binding, Competitive / Q000187:drug effects; D015153:Blotting, Western; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D018500:Diabetes Insipidus, Nephrogenic / Q000188:drug therapy* / Q000235:genetics; D004285:Dogs; D004591:Electrophoresis, Polyacrylamide Gel; D049452:Green Fluorescent Proteins / Q000096:biosynthesis / Q000235:genetics; D007150:Immunohistochemistry; D007211:Indoles / Q000494:pharmacology; D007668:Kidney / Q000378:metabolism*; D018832:Molecular Chaperones / Q000494:pharmacology*; D009025:Morpholines / Q000494:pharmacology; D009154:Mutation; D011759:Pyrrolidines / Q000494:pharmacology; D017483:Receptors, Vasopressin / Q000235:genetics*; D013141:Spiro Compounds / Q000494:pharmacology; D014162:Transfection
D065092:Antidiuretic Hormone Receptor Antagonists; D000954:Antigens, Surface; D007211:Indoles; D018832:Molecular Chaperones; D009025:Morpholines; D011759:Pyrrolidines; D017483:Receptors, Vasopressin; D013141:Spiro Compounds; D049452:Green Fluorescent Proteins; C103281:satavaptan; C082134:relcovaptan; D000242:Cyclic AMP